http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
SiO MASERS AROUND WX PSC MAPPED WITH THE KVN AND VERA ARRAY (KaVA)
Yun, Youngjoo,Cho, Se-Hyung,Imai, Hiroshi,Kim, Jaeheon,Asaki, Yoshiharu,Chibueze, James O.,Choi, Yoon Kyung,Dodson, Richard,Kim, Dong-Jin,Kusuno, Kozue,Matsumoto, Naoko,Min, Cheulhong,Oyadomari, Miyak American Astronomical Society 2016 The Astrophysical journal Vol.822 No.1
<P>We present the first images of the v = 1 and v = 2 J = 1 -> 0 SiO maser lines taken with KaVA, i.e., the combined array of the Korean Very Long Baseline Interferometry (VLBI) Network and the VLBI Exploration of Radio Astrometry ( VERA), toward the OH/IR star WX Psc. The combination of long and short antenna baselines enabled us to detect a large number of maser spots, which exhibit a typical ring-like structure in both the v. =. 1 and v = 2 J = 1 -> 0 SiO masers as those that have been found in previous VLBI observational results of WX Psc. The relative alignment of the v = 1 and v = 2 SiO maser spots are precisely derived from astrometric analysis, due. to the absolute coordinates of the reference maser spot that were well determined in an independent astrometric observation with VERA. The superposition of the v = 1 and v = 2 maser spot maps shows a good spatial correlation between the v = 1 and v = 2 SiO maser features. Nevertheless, it is also shown that the v = 2 SiO maser spot is distributed in an inner region compared to the v - 1 SiO maser by about 0.5 mas on average. These results provide good support for the recent theoretical studies of the SiO maser pumping, in which both the collisional and the radiative pumping predict the strong spatial correlation and the small spatial discrepancy between the v = 1 and v = 2 SiO maser.</P>
Youngjoo Kim,Jin Seok Lee,Hyeok Jun Yun,Yong Sang Lee,Hang-Seok Chang 대한내분비외과학회 2023 The Koreran journal of Endocrine Surgery Vol.23 No.4
The transoral endoscopic thyroidectomy vestibular approach (TOETVA) is an effective treatment for thyroid nodules and cancer. The excellent cosmetic outcomes compared to conventional and other types of endoscopic thyroidectomies make TOETVA a highly popular choice in selected patients. However, the limited working space and indirect thyroid manipulation can result in unexpected complications. Here, we describe a case of track site seeding in a 47-year-old woman who underwent left hemithyroidectomy via TOETVA. The pathological diagnosis changed from follicular adenoma to invasive encapsulated follicular variant papillary thyroid cancer after cancer recurrence.
Lee, Youngjoo,Lee, Ki Hyeong,Lee, Geon Kook,Lee, Soo-Hyun,Lim, Kun Young,Joo, Jungnam,Go, Yun Jung,Lee, Jin Soo,Han, Ji-Youn Korean Cancer Association 2017 Cancer Research and Treatment Vol.49 No.4
<P><B>Purpose</B></P><P>This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung cancer (NA-NSCLC).</P><P><B>Materials and Methods</B></P><P>Patients with advanced NA-NSCLC who progressed after one or two chemotherapy regimens were randomly assigned to a simvastatin (40 mg/day) plus afatinib (40 mg/day) (AS) arm or to an afatinib (A) arm. The primary endpoint was response rate (RR).</P><P><B>Results</B></P><P>Sixty-eight patients were enrolled (36 in the AS arm and 32 in the A arm). The RR was 5.7% (95% confidence interval [CI], 0.7 to 19.2) for AS and 9.4% (95% CI, 2.0 to 25.0) for A (p=0.440). In arms AS and A, the median progression-free survival (PFS) was 1.0 versus 3.6 months (p=0.240) and the overall survival was 10.0 months versus 7.0 months (p=0.930), respectively. Skin rash, stomatitis, and diarrhea were the most common adverse events in both arms. More grade 3 or 4 diarrhea was observed in arm A (18.8% vs. 5.6% in arm AS). In all patients, the median PFS for treatment including afatinib was not correlated with the status of epidermal growth factor receptor (<I>EGFR</I>) mutation (p=0.122), <I>EGFR</I> fluorescence <I>in situ</I> hybridization (p=0.944), or EGFR immunohistochemistry (p=0.976). However, skin rash severity was significantly related to the risk of progression for afatinib (hazard ratio for skin rash grade ≥ 2 vs. grade < 2, 0.44; 95% CI, 0.25 to 0.78; p=0.005).</P><P><B>Conclusion</B></P><P>There were no significant differences in the efficacy between AS and A arms in patients with NA-NSCLC.</P>
The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma
Lee, Youngjoo,Jeon, Jae Hyun,Goh, Sung-Ho,Roh, Hanseong,Yun, Ji-Young,Kwon, Nak-Jung,Choi, Jin Ho,Yang, Hee Chul,Kim, Moon Soo,Lee, Jong Mog,Lee, Geon Kook,Han, Ji-Youn Elsevier 2019 Lung cancer Vol.136 No.-
<P><B>Abstract</B></P> <P><B>Objectives</B></P> <P>Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.</P> <P><B>Material and methods</B></P> <P>We screened 3,241 lung cancer patients who (a) underwent curative resection at National Cancer Center (Goyang, Korea) between 2001–2014, and (b) completed a pre-designed interview about family/smoking history at the time of diagnosis and identified 604 female never smoker lung adenocarcinoma. A positive family history of cancer [categorized as pulmonary cancer (FH-PC) or non-pulmonary cancer (FH-NPC)] was defined as a self-reported history of cancer in first-degree relatives. Survival data were followed up until January 2017. Multiplexed targeted next-generation sequencing was performed for genetic profiling.</P> <P><B>Results</B></P> <P>Of 604 patients, 29.1% (n = 176) had a FH, including 132 (21.9%) with FH-NPC and 44 (7.3%) with FH-PC. Patients with the FH-NPC had a higher proportion of young patients (≤45 years) than those without the FH-NPC (FH-NPC, FH-PC, and no FH; 13.6%, 2.3%, and 8.2%, respectively; <I>P</I> = 0.032). Patients with the FH-NPC had an increased risk of recurrence (hazard ratio [HR]: 1.90; 95% confidence interval [CI]: 1.40–2.56; <I>P<</I>0.001) and death (HR: 1.67; 95% CI: 1.18–2.37; <I>P=</I>0.004). In contrast, the FH-PC had no prognostic effect on recurrence (HR: 1.23; 95% CI: 0.71–2.15; <I>P = 0.456</I>) and death (HR: 0.93; 95% CI: 0.45–1.91; <I>P=</I>0.838). Among three driver oncogene alterations, <I>EGFR</I> mutation was significantly associated with the FH-PC (53.8%, 84.1%, and 65.8%, respectively; <I>P</I> = 0.016), <I>ALK</I>/<I>ROS1</I>/<I>RET</I> fusions was significantly associated with the FH-NPC (13.7%, 0.0%, and 5.0%, respectively; <I>P</I> = 0.004), but <I>KRAS</I> mutation was not associated with any type of the FH (13.8% vs. 6.0% vs. 7.8%, respectively; <I>P</I> = 0.288).</P> <P><B>Conclusion</B></P> <P>The type of family history of cancer was associated with distinct clinocogenomic subtypes and prognosis of never-smoker lung adenocarcinoma.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Family history of cancer is related to distinct subtypes of never smoker lung cancer. </LI> <LI> <I>ALK/ROS1/RET</I> fusions are enriched in patients with family history of nonlung cancer. </LI> <LI> <I>EGFR</I> mutations are enriched in patients with family history of lung cancer. </LI> <LI> Family history of nonlung cancer is associated with poor prognosis after operation. </LI> </UL> </P>